Stock Research Monitor: VYGR, VTVT, and ZSAN

LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want a free Stock Review on VVUS sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com reexplores the Biotechnology industry, which uses biological systems or living organisms for the development of its products, mostly biopharmaceutical drugs. Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

VIVUS

Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79. The stock recorded a trading volume of 3.25 million shares, which was higher than its three months average volume of 1.27 million shares. The Company's shares have surged 105.87% in the last month and 77.39% over the last three months. The stock is trading 62.32% and 24.77% above its 50-day and 200-day moving averages, respectively. Moreover, shares of VIVUS, which develops and commercializes novel therapeutic products to address unmet medical needs in human health in the US and the EU, have a Relative Strength Index (RSI) of 62.84.

On May 01st, 2018, VIVUS announced that it has entered into a definitive agreement to acquire all product rights for PANCREAZE® (pancrelipase) Delayed-Release Capsules in the US and Canada held by Janssen Pharmaceuticals, Inc., subject to certain closing conditions, including Hart-Scott-Rodino review. This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Get the full research report on VVUS for free by clicking below at:

www.wallstequities.com/registration/?symbol=VVUS

Voyager Therapeutics

Cambridge, Massachusetts headquartered Voyager Therapeutics Inc.'s stock rose 2.53%, closing the day at $20.28 with a total trading volume of 297,175 shares. The Company's shares have advanced 8.92% in the past month and 126.34% over the past year. The stock is trading 6.82% and 12.36% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Voyager Therapeutics, which focuses on the development of treatments for patients suffering from severe neurological diseases, have an RSI of 57.65.

On May 10th, 2018, Voyager Therapeutics reported its Q1 2018 results. GAAP net loss for the quarter was $19.9 million; collaboration revenue was $0.9 million; research and development expenses were $14.9 million; and general and administrative expenses were $7.2 million. As of March 31st, 2018, cash, cash equivalents, and marketable debt securities were $218.2 million. Access the free research report on VYGR now by signing up at:

www.wallstequities.com/registration/?symbol=VYGR

vTv Therapeutics

On Tuesday, shares in High Point, North Carolina headquartered vTv Therapeutics Inc. recorded a trading volume of 179,053 shares. The stock ended the day 1.81% lower at $1.63. The Company's shares are trading below their 50-day moving average by 33.73%. Furthermore, shares of vTv Therapeutics, which discovers, develops, and sells orally administered small molecule drug candidates worldwide, have an RSI of 38.60.

On May 15th, 2018, vTv Therapeutics reported its results for Q1 ended March 31st, 2018. R&D expenses were $8.9 million in Q1 2018, G&A expenses were $2.3 million, and GAAP net loss per share was $0.30. As of March 31st, 2018, cash and cash equivalents were $6.5 million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VTVT at:

www.wallstequities.com/registration/?symbol=VTVT

Zosano Pharma

Fremont, California headquartered Zosano Pharma Corp.'s stock climbed 2.05%, finishing yesterday's session at $3.99 with a total trading volume of 176,494 shares. The stock is trading below their 50-day moving average by 36.81%. Shares of the Company, which focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology, have an RSI of 40.52.

On May 22nd, 2018, Zosano Pharma announced that Steven A. Elms, Managing Partner at Aisling Capital, has been appointed to its Board of Directors. Aisling was a lead investor in the follow-on financing that the Company recently completed in early-April. Aspiring Member, please take a moment to register below for your free research report on ZSAN at:

www.wallstequities.com/registration/?symbol=ZSAN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities